Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul;35(7):e15541.
doi: 10.1111/dth.15541. Epub 2022 May 13.

Case report: Dupilumab for the treatment of bullous pemphigoid

Mengxin Wang  1   2 , Juan Wang  1 , Bingjun Shi  1
Affiliations
Case Reports

Case report: Dupilumab for the treatment of bullous pemphigoid

Mengxin Wang et al. Dermatol Ther. 2022 Jul.

Abstract

Bullous pemphigoid (BP) is an inflammatory subepidermal blistering disease with rising prevalence in the elderly individuals. Cytokines associated with Th2-type immune response play an important role in the pathogenesis of BP. The traditional glucocorticoids and immunosuppressants are recommended as first-line drugs, but their therapeutic use is limited by numerous adverse effects. Dupilumab is a humanized monoclonal antibody that targets IL-4 and IL-13. It has recently been approved for the treatment of atopic dermatitis and may be an attractive therapeutic option for BP as well. Herein, we report two cases of BP treated with dupilumab. It was effective and well tolerated. Further research is needed to assess the efficacy of dupilumab in BP patients.

Keywords: bullous pemphigoid; dupilumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Maglie R, Genovese G, Solimani F, et al. Immune-mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review. Am J Clin Dermatol. 2020;21(6):833-854.
    1. Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016;77(1):189-195.
    1. Sears AV, Woolf RT, Gribaleva E, et al. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated. Br J Dermatol. 2021;184(4):755-757.
    1. Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequencyof interleukin-10-producing cells. J Invest Dermatol. 2001;17(5):1097-1102.
    1. Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis-a systematic review. J Dermatolog Treat. 2021;32(1):19-28.

Publication types

MeSH terms

Substances

LinkOut - more resources